Disc Medicine, Inc. (IRON)

US — Healthcare Sector
Peers: BEAM  RXRX  NTLA  ADPT  TVTX  ARQT  CDTX  IDYA  IBRX  BLTE 

Automate Your Wheel Strategy on IRON

With Tiblio's Option Bot, you can configure your own wheel strategy including IRON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IRON
  • Rev/Share 0.0
  • Book/Share 17.5353
  • PB 4.9748
  • Debt/Equity 0.0503
  • CurrentRatio 32.1068
  • ROIC -0.2622

 

  • MktCap 3032775459.0
  • FreeCF/Share -3.8703
  • PFCF -22.3729
  • PE -21.0153
  • Debt/Assets 0.0465
  • DivYield 0
  • ROE -0.266

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation IRON Truist -- Buy -- $86 July 21, 2025
Resumed IRON Morgan Stanley -- Overweight -- $85 July 3, 2025
Resumed IRON Raymond James -- Strong Buy -- $89 June 11, 2025
Initiation IRON TD Cowen -- Buy -- -- Feb. 27, 2025
Initiation IRON Jefferies -- Buy -- $89 Oct. 23, 2024
Initiation IRON Scotiabank -- Sector Outperform -- -- Oct. 16, 2024
Initiation IRON Wells Fargo -- Overweight -- $75 Aug. 22, 2024

News

Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?
IRON
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 26.3% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
IRON
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of the upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Disc is selling 2,619,049 shares of common stock and pre-funded warrants to purchase 59,523 shares of common stock and AI DMI LLC (the Selling Stockholder) is selling 297,619 shares …

Read More
image for news Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value
IRON
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive

Disc Medicine receives a "Strong Buy" rating due to significant progress with bitopertin for EPP and XLP treatment. IRON submitted an NDA for bitopertin under Accelerated Approval, supported by positive BEACON and AURORA phase 2 study results showing reduced PPIX and improved QoL. The company earned a rare Commissioner's National Priority Review Voucher (CNPV), potentially expediting FDA review to as little as 1-2 months.

Read More
image for news Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
IRON
Published: October 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will present clinical data as a poster presentation at the upcoming 2025 American Society of Nephrology (ASN) Kidney Week, which will be held in Houston, TX on November 6-9, 2025.

Read More
image for news Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
IRON
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). Disc submitted the NDA under the FDA's accelerated approval pathway using reduction of protoporphyrin IX (PPIX) as a surrogate endpoint and requested a Priority Review based on bitopertin's potential to address the …

Read More
image for news Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
IRON
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics.

Read More
image for news Disc Medicine Appoints Nadim Ahmed to its Board of Directors
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
IRON
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2025 Congress, which will be held in Milan, Italy on June 12-15, 2025.

Read More
image for news Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
IRON
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know
IRON
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 68.8% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
IRON
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a recap of recent program and corporate developments.

Read More
image for news Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Disc Medicine to Participate in Upcoming Investor Conferences
IRON
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences:

Read More
image for news Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
IRON
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Read More
image for news Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

About Disc Medicine, Inc. (IRON)

  • IPO Date 2020-08-12
  • Website https://www.discmedicine.com
  • Industry Biotechnology
  • CEO John D. Quisel
  • Employees 94

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.